Craig-Hallum raised the price target for Delcath Systems (NASDAQ:DCTH) to $21.00 from the previous $18.00, while maintaining a Buy rating on the stock. The firm's analyst cited Delcath's strong ...

Craig-Hallum raised the firm’s price target on Koru Medical (KRMD) to $6 from $5 and keeps a Buy rating on the shares. Koru Medical’s Q4 ...

In a report released today, Jason Kreyer from Craig-Hallum maintained a Buy rating on Magnite (MGNI – Research Report). The company’s shares ...

Craig Hallum has recently reduced Babcock & Wilcox Enterprises Inc (BW) stock to Hold rating, as announced on November 10, 2023, according to Finviz. Earlier, on July 19, 2022, Craig Hallum had ...

Craig Hallum has recently reduced LivePerson Inc (LPSN) stock to Hold rating, as announced on November 8, 2024, according to Finviz. Earlier, on February 29, 2024, ROTH MKM had reduced the stock from ...

Fintel reports that on January 14, 2025, Craig-Hallum initiated coverage of LifeVantage (NasdaqCM:LFVN) with a Buy ...

IonQ stock surged thanks to new bullish coverage from an analyst firm today. Craig-Hallum reiterated a buy rating on the stock and raised its one-year price target from $22 per share to $45 per share.

Rigetti Computing: Craig-Hallum initiated coverage of the Berkeley, Calif.-based company with a Buy rating and $12 price target. Analysts led by Richard Shannon said quantum computing has an ...

Craig-Hallum began coverage on Rigetti Computing (NASDAQ:RGTI) noting the company's potential to lead in the revolutionary quantum computing sector with a "Buy" rating and a $12 price target.

Shares of NASDAQ SOPH opened at $3.10 on Wednesday. SOPHiA GENETICS has a 1 year low of $2.70 and a 1 year high of $7.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 ...

https://www.tipranks.com/news/the-fly/pegasystems-price-target-raised-to-115-from-90-at-rbc-capital As previously reported, Craig-Hallum upgraded Rimini Street (RMNI ...

Craig-Hallum launched its coverage of Clover Health Investments (NASDAQ:CLOV) with a Buy recommendation and $6 per share target on Tuesday despite the managed care firm's over three-fold rise in ...